

STERLING BIOTECH LIMITED
REGD. OFFICE: 43, ATLANTA, NARIMAN POINT, MUMBAI - 400 021

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE THIRD QUARTER ENDED 30TH SEPTEMBER, 2009

(Rs.in Lacs)

Sr. No.	Particulars	Quarter ended	Corresponding	NINE Months	Corresponding	For the Year
		30/09/2009	Quarter ended	Ended	NINE Months	Ended
		Unaudited	30/09/2008	30/09/2009	Ended	Ended
			Unaudited	Unaudited	30/09/2008	31/12/2008
				Unaudited	Unaudited	Audited
1	Income					
	a) Net Sales/Income from Operations	36,254.97	30,166.97	106,976.11	84,764.87	117,838.07
	b) Other Operating Income	113.85	198.23	393.20	767.08	1,003.26
	c) Total	36,368.82	30,365.20	107,369.31	85,531.95	118,841.33
2	Expenditure					
	a) (Increase)/decrease in stock in trade and work in progress	(5,697.28)	1,501.91	(14,209.92)	(535.17)	313.09
	b) Consumption of raw materials	21,144.95	9,016.47	59,546.79	29,819.07	42,153.95
	c) Employees Cost	1,014.21	875.06	2,979.61	2,578.29	3,522.48
	d) Depreciation	3,255.67	2,814.09	9,269.45	7,833.88	10,715.18
	e) Other expenditure	7,295.24	5,450.32	21,360.67	15,426.23	21,718.36
	f) Total	27,012.79	19,657.85	78,946.60	55,122.30	78,423.06
3	Profit from Operations before Other Income and Interest (1-2)	9,356.03	10,707.35	28,422.71	30,409.65	40,418.27
4	Other Income	0.00	0.00	0.00	0.00	0.00
5	Profit before Interest (3+4)	9,356.03	10,707.35	28,422.71	30,409.65	40,418.27
6	Interest	3,686.15	1,237.21	9,793.77	3,478.40	5,920.71
7	Profit (+) / Loss (-) from Ordinary Activities before tax (5-6)	5,669.88	9,470.14	18,628.94	26,931.25	34,497.56
8	Tax expense					
	a) Current	925.00	1,050.00	2,685.00	3,000.00	3,750.00
	b) Deferred	425.00	2,000.00	2,225.00	5,700.00	7,550.00
	c) Fringe Benefit	0.00	12.00	12.50	35.00	47.50
	d) Total	1,350.00	3,062.00	4,922.50	8,735.00	11,347.50
9	Net Profit (+)/Loss (-) from Ordinary Activities after tax (7-8)	4,319.88	6,408.14	13,706.44	18,196.25	23,150.06
10	Extraordinary Items	222.18	283.16	788.50	849.48	1,132.64
11	Net Profit (+)/Loss (-) for the period (9-10)	4,097.70	6,124.98	12,917.94	17,346.77	22,017.42
12	Prior year adjustment	0.00	0.00	0.00	0.00	99.29
13	Profit available for appropriation	4,097.70	6,124.98	12,917.94	17,346.77	21,918.13
14	Paid-up equity share capital (Face Value of Re.1/- per share)	2,501.97	2,397.58	2,501.97	2,397.58	2,437.98
15	Reserves excluding Revaluation Reserves as per balance sheet.					170,359.64
16	Earnings Per Share (EPS)					
	a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.	1.73	2.67	5.48	7.59	9.50
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.	1.64	2.55	5.16	7.24	9.03
17	Public Shareholding					
	- Number of shares	133,666,531	123,228,193	133,666,531	123,228,193	127,267,548
	- Percentage of shareholding	53.42%	51.40%	53.42%	51.40%	52.20%
18	Promoters and Promoter Group Shareholding					
	a) Pledged/Encumbered					
	Number of shares	30,527,000		30,527,000		32,488,136
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	34.29%		34.29%		36.49%
	Percentage of shares (as a % of the total share capital of the Company)	12.20%		12.20%		13.33%
	b) Non-encumbered					
	Number of shares	58,507,694		58,507,694		56,546,558
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	65.71%		65.71%		63.51%
	Percentage of shares (as a % of the total share capital of the Company)	23.38%		23.38%		23.19%

STERLING BIOTECH LIMITED
REGD. OFFICE: 43, ATLANTA, NARIMAN POINT, MUMBAI - 400 021

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE THIRD QUARTER ENDED 30TH SEPTEMBER, 2009

Notes:

- 1 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- 2 The above Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors in its meeting held on 31st October, 2009.
- 3 The Statutory Auditors have carried out a limited review of the financial results for the quarter ended 30th September, 2009
- 4 During the Quarter the Company has issued 964,323 equity shares of Re.1/- each pursuant to conversion of FCCBs.
- 5 The number of investor complaints for the quarter ended on 30th September, 2009 were : Opening - NIL, Received - 22, Disposed off - 22, and Balance - NIL.
- 6 Previous period figures have been regrouped/reclassified, wherever necessary.

For and on Behalf of
STERLING BIOTECH LIMITED

Place : Mumbai
Date : 31st October, 2009.

Chetan J. Sandesara
Joint Managing Director